Inactive Instrument

News CanaQuest Medical Corp. Other OTC

Equities

CANQF

CA1372201097

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

CanaQuest Announces Key Appointments to Team to Drive CQ-001 through Clinical Trials	06-11	AQ
CanaQuest Medical Corp. Announces Appointment of Dr. Paul Dick, Chairman of Advisory Board	06-11	CI
NHL Alumni Association Partners with CanaQuest and NEEKA Health to Conduct Studies for Anxiety and Quality of Life in Former NHL Players	31/10/23	CI
CanaQuest Medical Corp. cancelled the transaction announced on October 26, 2022	25/10/23	CI
CANAQUEST Announces Award of European Cannabinoid Patent	20/09/23	AQ
CanaQuest Medical Corp. Announces Award of European Cannabinoid Patent	19/09/23	CI
CanaQuest Awarded Best Global Medical Cannabinoid Development Company 2023 by UK-based Global Health and Pharma for their 8th Annual Healthcare and Pharmaceutical Program	27/07/23	AQ
CanaQuest Achieves Statistically Significant Reduction of Seizures for Epilepsy Compared to Standard CBD	08/12/22	CI
CanaQuest Medical Corp. announced a financing transaction	25/10/22	CI
CanaQuest Medical Corp. Launches Mentanine (R) (Cannabidiol + IP Formula) in the US	08/09/22	CI
CanaQuest Medical : Interim Consolidated Consolidated Financial Statements (unaudited) - June 30, 2022	08/08/22	PU
CanaQuest Medical : Attorney Letter	18/07/22	PU
CanaQuest Medical : Financial Statements (unaudited) - March 31, 2022	14/06/22	PU
CanaQuest Medical Corp. Appoints Rob Rinderman as New Director of Communications	07/04/21	CI
Canaquest Signs Medicinal Cannabis Education Partnership with the Canadian Cannabis Dispute Resolution Centre	11/03/21	CI
CANAQUEST MEDICAL CORP Announces New Production and Distribution Agreement with PurCann Pharma and SiliCycle Inc	02/02/21	CI
CANAQUEST MEDICAL CORP SECURES APPROVAL FOR LISTING ON THE OCMX™, AN ONLINE INVESTOR AND FINANCIAL CONNECTION PORTAL	17/09/20	GL
UPDATE: CANAQUEST MEDICAL CORP FILES PROVISIONAL PATENT FOR MENTANINE® - OMEGA-3 & PURE CANNABIDIOL (“CBD”) FORMULATION BOOSTING MENTAL HEALTH EFFICACY WHILE MINIMIZING CBD DOSAGE	14/07/20	GL
CANAQUEST MEDICAL CORP FILES PROVISIONAL PATENT FOR MENTANINE® - OMEGA-3 & PURE CANNABIDIOL (“CBD”) FORMULATION BOOSTING MENTAL HEALTH EFFICACY WHILE MINIMIZING CBD DOSAGE	14/07/20	GL
CanaQuest Medical Corp. Files A Provisional Cannabidiol/Omega-3 Patent, Trade Named Mentanine®	14/07/20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News CanaQuest Medical Corp. Other OTC

Equities

CANQF

CA1372201097

Summary

Filters